Novartis recently announced encouraging data from a clinical trial evalutating the efficacy of once-daily Ultibro Breezhaler (indacaterol/glycopyrronium bromide) for reducing chronic obstructive pulmonary disease (COPD) flare-ups. The report was published in the New England ... Read more